Pfizer and Biontec Announce Development of a Coronavirus Vaccine 90% Effective
"Pfizer" and "BioNTech" announced that the vaccine against the emerging corona virus "Covid-19" that they are developing is 90% effective, after preliminary analysis of the results of the third phase of clinical trials, which is the last before presenting Request his license.
Where it is possible that the vaccine will be launched next month and before the end of this year, which constitutes a glimmer of hope for the international community and its suffering for months in the face of the epidemic.
The company said that the analysis found that the vaccine was more than 90% effective in preventing disease among the trial volunteers, who had no evidence of a previous infection with the Coronavirus.
If these results are proven, this level of protection would put this vaccine on par with highly effective childhood vaccines for diseases like measles, and the company said no serious safety concerns were noted.
Pfizer plans to seek emergency permission from the US Food and Drug Administration to manufacture a two-dose vaccine later this month, after it collects safety data.
By the end of the year, company executives said, it will have manufactured enough doses to immunize 15 to 20 million people.
The two companies said in a joint statement that the effectiveness of the vaccine was measured by comparing the number of participants who were infected with the emerging coronavirus in the group that received the vaccine and the number of infected people in another group who received a placebo vaccine 7 days after receiving the second dose and 28 days after receiving the first dose. Which developed the vaccine with the German pharmaceutical company and Biontec only a few details of its clinical trial based on the first official review of data by an external panel of experts.